Phase III trial results due for new use for Erbitux

03/19/2007 |

ImClone Systems and partner Bristol-Myers Squibb expect results in the next few weeks on whether their cancer drug shows positive Phase III trial results for treating pancreatic cancer. One analyst said the drug could have an upside in peak sales of $100 million to $250 million if the results are positive.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA